1-ethyl-2-(4-methoxyphenyl)-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-6-methoxyindole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-ethyl-2-(4-methoxyphenyl)-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-6-methoxyindole
• 英文别名: 1-ethyl-2-(4-methoxyphenyl)-3-[4-[2-(piperid-1-yl)ethoxy]benzoyl]-6-methoxyindole；l-ethyl-2-(4-methoxyphenyl)-3-[4-[2-(piperidin-1-yl)ethoxy]benzoyl]-6-methoxyindole；[1-Ethyl-6-methoxy-2-(4-methoxyphenyl)indol-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone
• 化学式: C₃₂H₃₆N₂O₄
• 分子量: 512.649
• InChiKey: RDFQQLFSBGBRFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  52.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] SELECTIVE DOPAMIN D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION<br/>[FR] AGONISTES SELECTIFS DU RECEPTEUR DE LA DOPAMINE D3 POUR TRAITER LES TROUBLES D'ORDRE SEXUEL
  申请人：PFIZER LTD

  公开号：WO2003051370A1

  公开（公告）日：2003-06-26

  The use of a composition comprising a selective dopamine D3 receptor agonist, wherein said dopamine D3 receptor agonist is at least about 15-times more functionally selective for a dopamine D3 receptor as compared with a dopamine D2 receptor when measured using the same functional assay, in the preparation of a medicament for the treatment and/or prevention of sexual dysfunction.

  使用一种包含选择性多巴胺D3受体激动剂的组合物，其中所述的多巴胺D3受体激动剂在使用相同的功能性测定时，与多巴胺D2受体相比至少具有15倍的功能选择性，用于制备治疗和/或预防性功能障碍的药物。
• Bicyclic bradykinin receptor antagonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0707852A2

  公开（公告）日：1996-04-24

  This invention also provides methods for treating or preventing conditions associated with an excess of bradykinins which methods comprise administration of one or more of the substituted indoles, benzofurans, or benzothiophenes described in this invention.

  本发明还提供了治疗或预防与缓激肽过量有关的疾病的方法，这些方法包括施用一种或多种本发明所述的取代吲哚、苯并呋喃或苯并噻吩。
• Compositions for treating resistant tumors
  申请人：ELI LILLY AND COMPANY

  公开号：EP0709090A2

  公开（公告）日：1996-05-01

  The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.

  本发明提供了通过用取代的吲哚、苯并呋喃、苯并噻吩、萘或二氢萘处理需要所述处理的哺乳动物来逆转耐药性肿瘤的多药耐药性的方法。本发明还提供了治疗哺乳动物肿瘤的方法，其中包括向需要治疗的哺乳动物施用取代的吲哚、苯并呋喃、苯并噻吩、萘或二氢萘，并与溶瘤剂结合使用。
• Compositions for inhibiting neuropeptide y receptors
  申请人：ELI LILLY AND COMPANY

  公开号：EP0716854A2

  公开（公告）日：1996-06-19

  This invention provides methods for treating or preventing a condition associated with an excess of neuropeptide Y which methods comprise administration of one or more substituted benzofurans, benzothiophenes or indoles.

  本发明提供了治疗或预防与神经肽 Y 过量有关的疾病的方法，这些方法包括施用一种或多种取代的苯并呋喃、苯并噻吩或吲哚。
• Methods of treating neuropeptide Y-associated conditions
  申请人：ELI LILLY AND COMPANY

  公开号：EP0754464A2

  公开（公告）日：1997-01-22

  This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering a naturally occurring obesity protein. Another embodiment of this invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering a naturally occurring obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

  本发明描述了治疗与神经肽Y过量有关的病症的方法，其中包括施用天然肥胖蛋白。本发明的另一个实施方案描述了治疗与神经肽 Y 过量有关的病症的方法，其中包括将天然肥胖蛋白与神经肽 Y 拮抗剂结合使用。本发明证明，肥胖蛋白通过减少下丘脑产生的神经肽Y发挥作用。